中国癌症杂志 ›› 2013, Vol. 23 ›› Issue (11): 868-873.doi: 10.3969/j.issn.1007-3969.2013.11.003

• 论著 • 上一篇    下一篇

雌激素通过激活AKT通路产生的细胞因子增强子宫内膜癌细胞增殖能力

陆媛媛1,张洁清2,梁少凤2,李力2   

  1. 1. 广西贵港市人民医院妇科,广西 贵港537100;
    2. 广西医科大学附属肿瘤医院妇瘤科,广西 南宁 530021
  • 出版日期:2013-11-25 发布日期:2014-02-18
  • 通信作者: 张洁清 E-mail:zjq201008@hotmail.com
  • 基金资助:
    国家自然科学基金资助项目(No:81160318);
    广西自然科学基金(No:桂科回0991016)。

Estradiol enhances the proliferation of endometrial cancer cells by producing angiogenesis by activating AKT pathway

LU Yuan-yuan1,ZHANG Jie-qing2,LIANG Shao-feng2,LI Li2   

  1. 1.Department of Gynecology, Guigang City People’s Hospital, Guigang Guangxi 537100, China;
    2.Department of Gynecologic Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning Guangxi 530021, China
  • Published:2013-11-25 Online:2014-02-18
  • Contact: ZHANG Jie-qing E-mail: zjq201008@hotmail.com

摘要:

背景与目的:目前认为子宫内膜癌的发生可能与无拮抗的雌激素长期作用有关,但雌激素如何调节细胞增殖的作用机制尚不清楚。AKT信号转导通路是细胞生存和增殖的一个重要调节信号。本研究探讨在子宫内膜癌细胞HEC-1A中,雌二醇能否通过激活AKT通路产生细胞因子,以及其对细胞增殖能力的影响。方法:蛋白质印迹法(Western blot)技术检测雌二醇作用HEC-1A细胞后AKT活化情况,以及AKT抑制剂、ER抑制剂对AKT活化的影响。荧光定量PCRELISA技术检测雌二醇(E2)作用于HEC-1A细胞30 min后;或雌激素受体抑制剂(ER)AKT抑制剂(AKT)分别预处理细胞1 h后再加入雌二醇作用30 min后,细胞内血管内皮生长因子受体(VEGF)bFGFIL-8基因mRNA表达及细胞培养上清液中蛋白表达。细胞集落形成实验、流式细胞仪检测细胞周期的变化,CFSE法检测细胞增殖能力。结果:E2组的AKT活化比值较对照组显著升高(P=0.006 2)ER组和AKT组的AKT活性比值较E2组显著降低(P=0.006 0P=0.006 4),但不能完全抑制雌二醇作用。E2组的VEGFbFGFIL-8 mRNA或蛋白的表达均明显高于对照组(P<0.01);在ER组及AKT组中VEGFbFGFIL-8 mRNA或蛋白的表达均明显低于E2(P<0.05);雌二醇作用HEC-1A细胞后,细胞增殖数明显增多,细胞周期加快(P<0.01)结论:HEC-1A细胞,雌二醇可能通过激活AKT信号通路产生VEGFbFGFIL-8因子,从而增强肿瘤细胞的增殖能力。

关键词: 雌二醇, 子宫内膜癌, AKT, 增殖

Abstract:

Background and purpose: The occurrence of endometrial cancer may be related to the persistent stimulus of endogenous and exogenous estrogen without progesterone antagonist. But how does estrogen regulate cell proliferation is still unknown. AKT pathway is the most important signal transduction way to mediate proliferation in the cells. The main aim was to study whether estradiol induces the expression of VEGF, bFGF and IL-8 in the endometrial cancer HEC-1A cells by activating AKT, and its effect on proliferation. Methods: Western blot was used to detect the expression of AKT protein in HEC-1A cells after estradiol stimulation, AKT inhibitor or ER inhibitor stimulation followed by estradiol. Real-time PCR and ELISA were used to detect the gene and protein expression of VEGF, bFGF and IL-8 in different inhibitors. Cell colony formation assay, flow cytometry and CFSE assay were used to examine the proliferation in HEC-1A cells. Results: The expression of p-AKT protein in HEC-1A cells after stimulation with estradiol was markedly higher than that in the control group (P=0.006 2); the expression of p-AKT protein in AKT inhibitor group and ER inhibitor group were significantly decreased than that in estradiol group (P=0.006 0, P=0.006 4). qPCR and ELISA showed the mRNA and protein expression of VEGF, bFGF, IL-8 in estradiol group were significantly increased than that in control group (P<0.05); The expressions of VEGF, bFGF, IL-8 in AKT inhibitor group and ER inhibitor group were significantly decreased than that in estradiol group (P<0.01). The abilities of proliferation and cell cycle were significantly increased in HEC-1A cells after estradiol stimulation. Conclusion: Estrogen induces the production of VEGF, bFGF and IL-8 through activating AKT signal pathway.

Key words: Estrogen, Endometrial cancer, AKT, Proliferation